[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100425820":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":25,"locations":34,"responsibleParty":61,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Centre Henri Becquerel","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Monitoring of Circulating Tumor DNA",null,[12],"Other: Circulating tumor DNA monitoring",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Circulating tumor DNA monitoring","Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy",[9],[19,22],{"name":20,"affiliation":5,"role":21},"VINCENT CAMUS, MD","PRINCIPAL_INVESTIGATOR",{"name":23,"affiliation":24,"role":21},"PIERRE SESQUES, MD","Centre Hospitalier Lyon Sud",[26,30],{"name":20,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+33232082497","vincent.camus@chb.unicancer.fr",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"RICHARD DORIANE, PhD","+33232082985","doriane.richard@chb.unicancer.fr",[35,50],{"facility":24,"status":36,"city":37,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"NOT_YET_RECRUITING","Lyon","France","FR",{"type":41,"coordinates":42},"Point",[43,44],4.84789,45.74906,{"lat":44,"lon":43},[47],{"name":23,"role":27,"phone":48,"phoneExt":10,"email":49},"+33478864301","pierre.sesques@chu-lyon.fr",{"facility":5,"status":51,"city":52,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"RECRUITING","Rouen",{"type":41,"coordinates":54},[55,56],1.09932,49.44313,{"lat":56,"lon":55},[59],{"name":20,"role":27,"phone":60,"phoneExt":10,"email":29},"+33232082947",{"type":62,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100425820","circulating-tumor-dna-in-primary-mediastinal-large-b-cell-lymphoma-pmbl-100425820",false,"NCT04824950","Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)","CAMIL","Inclusion Criteria:\n\n* Patient over 18 years of age,\n* Suffering from a diffuse primary B lymphoma of the mediastinum, newly diagnosed locally on a biopsy with anatomopathological analysis according to the recommendations of the WHO 2016 classification of hematological malignancies,\n* All stages (I-IV)\n* All IPI scores (0-5)\n* With mediastinal involvement,\n* Untreated (apart from emergency corticosteroid therapy less than 2mg\u002Fkg\u002Fday for 7 days),\n* Treatment with R-CHOP-14 or R-ACVBP with PET-CT guided strategy (delta SUVmax) to be initiated,\n* Tumor fixation above liver background on pre-treatment FDG PET\u002FCT\u002FCT (Deauville score ≥4),\n* Having signed the informed consent prior to any study procedure\n* Affiliated or beneficiary of a social protection plan.\n\nExclusion Criteria:\n\n* Patient who has already started chemotherapy treatment,\n* Contraindication to FDG PET-CT,\n* No mediastinal involvement,\n* Positive HIV serology,\n* Positive hepatitis B or C serology with positive viral load,\n* Protected adult (under guardianship or curatorship),\n* Pregnant or breastfeeding women,\n* Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).","ALL","18 Years",{"count":73,"type":74},87,"ESTIMATED","INTERVENTIONAL",[77],"NA","The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving standard R-CHOP14 or R-ACVBP.",[80],"Primary Mediastinal Large B-cell Lymphoma",[80,82,83],"Circulating tumor DNA","Next Generation sequencing","2021-03-29",{"date":86,"type":87},"2021-04-01","ACTUAL",{"date":89,"type":74},"2021-03-22",{"date":91,"type":74},"2028-03-01",{"name":5,"class":6},2]